Document is current
Any future updates will be listed below
-
Authors
Caron, Jérôme
Pène, Véronique
Tolosa, Laia
Villaret, Maxime
Luce, Eléanor
Fourrier, Angélique
Heslan, Jean-Marie
Saheb, Samir
Bruckert, Eric
Gómez-Lechón, María José
Nguyen, Tuan Huy
Rosenberg, Arielle R.
Weber, Anne
Dubart-Kupperschmitt, Anne https://orcid.org/0000-0002-9326-4413
-
Funding
Funding for this research was provided by:
FP7 Health (FP7-HEALTH.2011.1.4-2-278152 “InnovaLiv”, FP7-HEALTH.2011.1.4-2-278152 “InnovaLiv”, FP7-HEALTH.2011.1.4-2-278152 “InnovaLiv”, FP7-HEALTH.2011.1.4-2-278152 “InnovaLiv”)
Agence Nationale de la Recherche (ANR-2010-RFCS-004 “Liv-iPS”, ANR-2010-RFCS-004 “Liv-iPS”., ANR-14-CE16-0026, ANR-10-IBHU-005)
Ministère de l'Enseignement Supérieur et de la Recherche (N/A)
Fondation pour la Recherche Médicale (FDT20160435349)
DHU Hepatinov (N/A, N/A)
Instituto de Salud Carlos III (Miguel Servet I Contract (CP16/00097))
Conseil Régional, Île-de-France (DIM Biothérapies)
Société Francaise d'Hématologie (N/A)
Région Pays de La Loire - Nantes Métropole (N/A)
- License Information
-
More Information
Article History
Received: 16 May 2019
Revised: 3 July 2019
Accepted: 14 July 2019
First Online: 29 July 2019
Ethics approval and consent to participate
: This study was performed in agreement with the French and European regulations. Appropriate ethical approval and written informed consent were obtained from the FH patient homozygous for the p.Q12X null mutation. No patient’s information is available in the laboratory, apart from his sex and age, personal identification is thus not possible. Ethical approval was obtained from INSERM clinical research committee and legal instances (Comité de protection des personnes and Afssaps).
: Not applicable
: The authors declare that they have no competing interests.
